Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01657162 · ClinicalTrials.gov registry record · Phase 3
Twenty-Four Month Extension Study of BA058-05-003 (Abaloparatide) in Participants With Osteoporosis
A Phase 3 study, sponsored by Radius Health.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,139
- Enrollment target
NCT01657162: Completed Phase 3 study, sponsored by Radius Health.
NCT01657162 is a Phase 3 study that has completed, run by Radius Health. The registered enrollment target is 1,139 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (48% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01657162, a Phase 3 study, has completed, sponsored by Radius Health.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,139 participants
- Enrollment target
Study Summary
The purpose of this study is to provide 24 months of standard of care data on participants previously enrolled in Study BA058-05-003 (NCT02653417).
Primary Outcome
Vertebral fractures were determined clinically and via protocol directed radiograph evaluation. Complete results for Study BA058-05-003 are reported in the ClinicalTrials.gov Study Record NCT02653417.
Interventions
- DRUG Alendronate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,139 participants |
| Start Date | 2012-11-20 |
| Est. Completion | 2016-10-03 |
| Phase | Phase 3 |
What the finished NCT01657162 record still lists
NCT01657162 is an interventional study that assigns participants to a tested intervention. Its 1,139 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (48% higher).
The record links to 0 conditions, and to 1 intervention - of which Alendronate is the first listed.
NCT01657162 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01657162 about?
NCT01657162 is a clinical study titled "Twenty-Four Month Extension Study of BA058-05-003 (Abaloparatide) in Participants With Osteoporosis". The purpose of this study is to provide 24 months of standard of care data on participants previously enrolled in Study BA058-05-003 (NCT02653417).
What is the current status of trial NCT01657162?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,139 participants. The study started on 2012-11-20. Estimated completion is 2016-10-03.
What interventions are being tested in trial NCT01657162?
The interventions under investigation include: Alendronate (DRUG).
Who is sponsoring clinical trial NCT01657162?
This trial is sponsored by Radius Health, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01657162's enrollment target sits among peer trials
1,139 243rd of 2000 higher than 1,758 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05894967 · 1,140 participants · NA
Moderators and Mediators of Perceptual Learning
- NCT06532487 · 1,140 participants · NA
Addressing Durable Health Disparities Through Critical Time Legal Interventions in Medically Underserved Latinx and Migrant Communities
- NCT06129864 · 1,145 participants · Phase 3
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
- NCT06676319 · 1,147 participants · Phase 2
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI